G1 Therapeutics, Inc. stock is up 135.82% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT.
G1 Therapeutics, Inc. engages in the discovery, development, and commercialization of small molecule therapeutics. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; and rintodestrant, an oral selective estrogen receptor degrader.